Sanofi to present new diabetes data at ADA meeting

Sanofi has announced plans to present the latest findings on its diabetes portfolio at the forthcoming scientific sessions of the American Diabetes Association (ADA), which take place in Chicago later this month.

More than 60 abstracts on established and investigational diabetes therapies and devices will be presented at the event between June 21st and 25th.

Data from a study on the efficacy and safety of the investigational insulin product U300 and the latest findings on the postprandial mechanism of action of Lyxumia will be showcased, as well as results from Origin, a seven-year trial involving the drug Lantus.

Sanofi will also discuss the performance of BGStar and iBGStar, its innovative blood glucose monitoring devices, which are available in 14 countries.

Pierre Chancel, senior vice-president for global diabetes at Sanofi, said: "The data being presented further support the company's leadership in integrated diabetes care and delivering personalised solutions that directly target the needs of people living with this disease."

Earlier this month, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that new safety data from the Origin trial should be added to Lantus' EU product label.